keyword
https://read.qxmd.com/read/37891842/prefrontal-glutathione-levels-in-major-depressive-disorder-are-linked-to-a-lack-of-positive-affect
#21
JOURNAL ARTICLE
Ruth O'Gorman Tuura, Andreas Buchmann, Christopher Ritter, Adrian Hase, Melanie Haynes, Ralph Noeske, Gregor Hasler
Major depressive disorder (MDD) is one of the most common neuropsychiatric disorders, with symptoms including persistent sadness and loss of interest. MDD is associated with neurochemical alterations in GABA, glutamate, and glutamine levels but, to date, few studies have examined changes in glutathione (GSH) in MDD. This study investigated changes in GSH in an unmedicated group of young adults, including 46 participants with current ( n = 12) or past MDD ( n = 34) and 20 healthy controls. Glutathione levels were assessed from GSH-edited magnetic resonance (MR) spectra, acquired from a voxel in the left prefrontal cortex, and depressive symptoms were evaluated with validated questionnaires and clinical assessments...
October 19, 2023: Brain Sciences
https://read.qxmd.com/read/37881420/a-comparison-between-single-and-double-dose-intravenous-ketamine-administration-in-bipolar-mood-disorder-a-double-blind-controlled-clinical-trial
#22
JOURNAL ARTICLE
Ali Talaei, Farhad Farid Hoseini, Meisam Mahdavi, Maryam Salehi, Asieh Karimani, Fahimeh Afzaljavan
Objective: As glutamatergic system dysfunction is involved in bipolar depression pathophysiology, the glutamate receptor modulators such as Ketamine have been applied as complementary medication for mood stabilizers. While the treatment is currently just the intravenous injection of a single dose, and there is no robust conclusion on Ketamine effectiveness or its side effects in bipolar patients, this study aimed to consider single- and double-dose intravenous injections of Ketamine in bipolar patients compared to the placebo...
October 2023: Iranian Journal of Psychiatry
https://read.qxmd.com/read/37732856/ketamine-use-in-pediatric-depression-a-systematic-review
#23
REVIEW
Shakila Meshkat, Joshua D Rosenblat, Roger C Ho, Taeho Greg Rhee, Bing Cao, Felicia Ceban, Kevork Danayan, Noah Chisamore, Joshua D Di Vincenzo, Roger S McIntyre
Pediatric depression is a common psychiatric disorder that is associated with significant morbidity and mortality. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with demonstrated antidepressant effects in the adult population, however, the efficacy and safety of ketamine for the treatment of pediatric depression remains poorly understood. Electronic databases were searched from inception to June 2022 to identify relevant articles. Six articles involving 46 participants with a mean age of 15...
November 2022: Psychiatry Research
https://read.qxmd.com/read/37689275/psilocybin-induces-acute-and-persisting-alterations-in-immune-status-in-healthy-volunteers-an-experimental-placebo-controlled-study
#24
JOURNAL ARTICLE
N L Mason, A Szabo, K P C Kuypers, P A Mallaroni, R de la Torre Fornell, J T Reckweg, D H Y Tse, N R P W Hutten, A Feilding, J G Ramaekers
Patients characterized by stress-related disorders such as depression display elevated circulating concentrations of pro-inflammatory cytokines and a hyperactive HPA axis. Psychedelics are demonstrating promising results in treatment of such disorders, however the mechanisms of their therapeutic effects are still unknown. To date the evidence of acute and persisting effects of psychedelics on immune functioning, HPA axis activity in response to stress, and associated psychological outcomes is preliminary. To address this, we conducted a placebo-controlled, parallel group design comprising of 60 healthy participants who received either placebo (n = 30) or 0...
September 7, 2023: Brain, Behavior, and Immunity
https://read.qxmd.com/read/37686891/folate-and-its-significance-in-depressive-disorders-and-suicidality-a-comprehensive-narrative-review
#25
REVIEW
Timur Liwinski, Undine E Lang
Depressive disorders pose significant challenges to global public health, necessitating effective prevention and management strategies. Notably, the occurrence of suicide frequently coincides with depressive episodes. Suicide is as a paramount global health concern that demands efficacious preventive strategies. Current psychiatric approaches heavily rely on pharmacological interventions but have had limited success in addressing the global burden of mental health issues. Suboptimal nutrition, with its impact on the neuroendocrine system, has been implicated in the underlying pathology of depressive disorders...
September 4, 2023: Nutrients
https://read.qxmd.com/read/37665079/recent-advances-in-the-study-of-the-neurobiological-mechanisms-behind-the-effects-of-physical-activity-on-mood-resilience-and-emotional-disorders
#26
EDITORIAL
Chong Chen, Shin Nakagawa
Physical activity (PA) significantly influences emotional wellbeing, from enhancing mood to counteracting emotional disorders such as depression and anxiety. This article offers an in-depth analysis of the neurobiological processes and theories underpinning the emotional benefits of PA which arise from exercise-induced physiological changes that simultaneously benefit brain function. We discuss the role of growth factors, neurotransmitters and biochemicals, as well as enhancements in mitochondrial biogenesis and antioxidant activity, and how they foster exercise performance and emotional health...
September 4, 2023: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://read.qxmd.com/read/37612364/acute-and-long-term-effects-of-adolescence-stress-exposure-on-rodent-adult-hippocampal-neurogenesis-cognition-and-behaviour
#27
Alessandra Borsini, Juliette Giacobbe, Gargi Mandal, Maura Boldrini
Adolescence represents a critical period for brain and behavioural health and characterised by the onset of mood, psychotic and anxiety disorders. In rodents, neurogenesis is very active during adolescence, when is particularly vulnerable to stress. Whether stress-related neurogenesis changes influence adolescence onset of psychiatric symptoms remains largely unknown. A systematic review was conducted on studies investigating changes in hippocampal neurogenesis and neuroplasticity, hippocampal-dependent cognitive functions, and behaviour, occurring after adolescence stress exposure in mice both acutely (at post-natal days 21-65) and in adulthood...
August 23, 2023: Molecular Psychiatry
https://read.qxmd.com/read/37564785/epigenetic-embedding-of-childhood-adversity-mitochondrial-metabolism-and-neurobiology-of-stress-related-cns-diseases
#28
REVIEW
Benedetta Bigio, Yotam Sagi, Olivia Barnhill, Josh Dobbin, Omar El Shahawy, Paolo de Angelis, Carla Nasca
This invited article ad memoriam of Bruce McEwen discusses emerging epigenetic mechanisms underlying the long and winding road from adverse childhood experiences to adult physiology and brain functions. The conceptual framework that we pursue suggest multidimensional biological pathways for the rapid regulation of neuroplasticity that utilize rapid non-genomic mechanisms of epigenetic programming of gene expression and modulation of metabolic function via mitochondrial metabolism. The current article also highlights how applying computational tools can foster the translation of basic neuroscience discoveries for the development of novel treatment models for mental illnesses, such as depression to slow the clinical manifestation of Alzheimer's disease...
2023: Frontiers in Molecular Neuroscience
https://read.qxmd.com/read/37488838/type-b-monoamine-oxidase-inhibitors-in-neurological-diseases-clinical-applications-based-on-preclinical-findings
#29
REVIEW
Marika Alborghetti, Edoardo Bianchini, Lanfranco De Carolis, Silvia Galli, Francesco E Pontieri, Domiziana Rinaldi
Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson's disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B monoamine oxidase inhibitors on non-motor symptoms of Parkinson's disease, such as mood deflection, cognitive impairment, sleep disturbances, and fatigue. Preclinical studies indicate that type-B monoamine oxidase inhibitors hold a strong neuroprotective potential in Parkinson's disease and other neurodegenerative diseases for reducing oxidative stress and stimulating the production and release of neurotrophic factors, particularly glial cell line-derived neurotrophic factor, which support dopaminergic neurons...
January 2024: Neural Regeneration Research
https://read.qxmd.com/read/37457832/plasma-metabolomics-by-nuclear-magnetic-resonance-reveals-biomarkers-and-metabolic-pathways-associated-with-the-control-of-hiv-1-infection-progression
#30
JOURNAL ARTICLE
León Gabriel Gómez-Archila, Martina Palomino-Schätzlein, Wildeman Zapata-Builes, Maria T Rugeles, Elkin Galeano
How the human body reacts to the exposure of HIV-1 is an important research goal. Frequently, HIV exposure leads to infection, but some individuals show natural resistance to this infection; they are known as HIV-1-exposed but seronegative (HESN). Others, although infected but without antiretroviral therapy, control HIV-1 replication and progression to AIDS; they are named controllers, maintaining low viral levels and an adequate count of CD4+ T lymphocytes. Biological mechanisms explaining these phenomena are not precise...
2023: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/37448433/gut-biome-and-mental-health-do-probiotics-work
#31
REVIEW
Jayakrishna S Madabushi, Priyal Khurana, Nihit Gupta, Mayank Gupta
Mental health conditions have been linked closely to an imbalance of microbiota in the gut, leading to disruption of the microbiome (dysbiosis). Several neurotransmitters, such as GABA (gamma-aminobutyric acid), serotonin, and glutamate, are produced in the gut, which are associated with anxiety and depressive symptoms. Mental health and the gut have been linked closely, and many mental illnesses have been associated with gut dysbiosis. Probiotics are marketed to improve gut health, act as mood enhancers, and be effective in reducing stress as unregulated over-the-counter supplements...
June 2023: Curēus
https://read.qxmd.com/read/37433745/helichrysum-stoechas-l-moench-reduces-body-weight-gain-and-modulates-mood-disorders-via-inhibition-of-silent-information-regulator-1-sirt1-by-arzanol
#32
JOURNAL ARTICLE
Vittoria Borgonetti, Clarissa Caroli, Paolo Governa, Brighenti Virginia, Federica Pollastro, Silvia Franchini, Fabrizio Manetti, Francisco Les, Victor López, Federica Pellati, Nicoletta Galeotti
The prevalence of obesity is steadily rising, making safe and more efficient anti-obesity treatments an urgent medical need. Growing evidence correlates obesity and comorbidities, including anxiety and depression, with the development of a low-grade inflammation in peripheral and central tissues. We hypothesized that attenuating neuroinflammation might reduce weight gain and improve mood. We investigated the efficacy of a methanolic extract from Helichrysum stoechas (L.) Moench (HSE), well-known for its anti-inflammatory properties, and its main constituent arzanol (AZL)...
July 11, 2023: Phytotherapy Research: PTR
https://read.qxmd.com/read/37428405/ketamine-counteracts-sevoflurane-induced-depressive-like-behavior-and-synaptic-plasticity-impairments-through-the-adenosine-a2a-receptor-erk-pathway-in-rats
#33
JOURNAL ARTICLE
Weiwei Yu, Ziyi Wu, Xingyue Li, Mengmeng Ding, Ying Xu, Ping Zhao
Ketamine is an ionic glutamic acid N-methyl-d-aspartate receptor (NMDAR) antagonist commonly used in clinical anesthesia, and its rapid and lasting antidepressant effect has stimulated great interest in psychology research. However, the molecular mechanisms underlying its antidepressant action are still undetermined. Sevoflurane exposure early in life might induce developmental neurotoxicity and mood disorders. In this study, we evaluated the effect of ketamine against sevoflurane-induced depressive-like behavior and the underlying molecular mechanisms...
July 10, 2023: Molecular Neurobiology
https://read.qxmd.com/read/37424423/effects-of-parental-verbal-abuse-experience-on-the-glutamate-response-to-swear-words-in-the-ventromedial-prefrontal-cortex-a-functional-1-h-magnetic-resonance-spectroscopy-study
#34
JOURNAL ARTICLE
Jae Hyun Yoo, Young Woo Park, Dohyun Kim, HyunWook Park, Bumseok Jeong
OBJECTIVE: Several lines of evidence indicate verbal abuse (VA) critically impacts the developing brain; however, whether VA results in changes in brain neurochemistry has not been established. Here, we hypothesized that exposure to recurrent parental VA elicits heightened glutamate (Glu) responses during the presentation of swear words, which can be measured with functional magnetic resonance spectroscopy (fMRS). METHODS: During an emotional Stroop task consisting of blocks of color and swear words, metabolite concentration changes were measured in the ventromedial prefrontal cortex (vmPFC) and the left amygdalohippocampal region (AMHC) of healthy adults (14 F/27 M, 23 ± 4 years old) using fMRS...
August 31, 2023: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://read.qxmd.com/read/37424412/the-role-of-glutamate-underlying-treatment-resistant-depression
#35
REVIEW
Jeongseop Kim, Tae-Eun Kim, Seung-Hwan Lee, Ja Wook Koo
The monoamine hypothesis has significantly improved our understanding of mood disorders and their treatment by linking monoaminergic abnormalities to the pathophysiology of mood disorders. Even 50 years after the monoamine hypothesis was established, some patients do not respond to treatments for depression, including selective serotonin reuptake drugs. Accumulating evidence shows that patients with treatment-resistant depression (TRD) have severe abnormalities in the neuroplasticity and neurotrophic factor pathways, indicating that different treatment approaches may be necessary...
August 31, 2023: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://read.qxmd.com/read/37385217/psilocybin-s-potential-mechanisms-in-the-treatment-of-depression-a-systematic-review
#36
REVIEW
Harrison J Lee, Vivian Wl Tsang, Brandon S Chai, Michelle Cq Lin, Andrew Howard, Christopher Uy, Julius O Elefante
Evidence suggests that psilocybin has therapeutic benefit for treating depression. However, there is little consensus regarding the mechanism by which psilocybin elicits antidepressant effects. This systematic review summarizes existing evidence. Ovid MEDLINE, EMBASE, psychINFO, and Web of Science were searched, for both human and animal studies, using a combination of MeSH Terms and free-text keywords in September 2021. No other mood disorders or psychiatric diagnoses were included. Original papers in English were included...
June 29, 2023: Journal of Psychoactive Drugs
https://read.qxmd.com/read/37381161/clinical-specificity-profile-for-novel-rapid-acting-antidepressant-drugs
#37
REVIEW
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri
Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants are not effective in all patients and often show a relevant response latency, with a range of adverse events, including weight gain and sexual dysfunction. Novel rapid agents were developed with the aim of overcoming at least in part these issues. Novel drugs target glutamate, gamma-aminobutyric acid, orexin, and other receptors, providing a broader range of pharmacodynamic mechanisms, that is, expected to increase the possibility of personalizing treatments on the individual clinical profile...
September 1, 2023: International Clinical Psychopharmacology
https://read.qxmd.com/read/37372414/divergent-transcriptomic-effects-of-allopregnanolone-in-postpartum-depression
#38
JOURNAL ARTICLE
Sarah A Rudzinskas, Maria A Mazzu, Crystal Edler Schiller, Samantha Meltzer-Brody, David R Rubinow, Peter J Schmidt, David Goldman
Brexanolone, a formulation of the neurosteroid allopregnanolone (ALLO), is approved for treating postpartum depression (PPD) and is being investigated for therapeutic efficacy across numerous neuropsychiatric disorders. Given ALLO's beneficial effects on mood in women with PPD compared to healthy control women, we sought to characterize and compare the cellular response to ALLO in women with ( n = 9) or without ( n = 10, i.e., Controls) past PPD, utilizing our previously established patient-derived lymphoblastoid cell lines (LCLs)...
June 8, 2023: Genes
https://read.qxmd.com/read/37333908/recommendations-for-selection-and-adaptation-of-rating-scales-for-clinical-studies-of-rapid-acting-antidepressants
#39
REVIEW
Christian Yavorsky, Elizabeth Ballard, Mark Opler, Jan Sedway, Steven D Targum, William Lenderking
The novel mechanisms of action (MOA) derived from some recently introduced molecular targets have led to regulatory approvals for rapid acting antidepressants (RAADs) that can generate responses within hours or days, rather than weeks or months. These novel targets include the N-methyl-D-glutamate receptor antagonist ketamine, along with its enantiomers and various derivatives, and the allosteric modulators of gamma-aminobutyric acid (GABA) receptors. There has also been a strong resurgence in interest in psychedelic compounds that impact a range of receptor sites including D1, 5-HT7, KOR, 5-HT5A, Sigma-1, NMDA, and BDNF...
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/37329495/insights-into-the-neurobiology-of-suicidality-explicating-the-role-of-glutamatergic-systems-through-the-lens-of-ketamine
#40
REVIEW
Adem Tevfik Can, Jules Shamus Mitchell, Megan Dutton, Maxwell Bennett, Daniel Francis Hermens, Jim Lagopoulos
Suicidality is a prevalent mental health condition, and managing suicidal patients is one of the most challenging tasks for healthcare professionals due to the lack of rapid-acting, effective psychopharmacological treatment options. According to the literature, suicide has neurobiological underpinnings that are not fully understood, and current treatments for suicidal tendencies have considerable limitations. To treat suicidality and prevent suicide, new treatments are required; to achieve this, the neurobiological processes underlying suicidal behaviour must be thoroughly investigated...
June 17, 2023: Psychiatry and Clinical Neurosciences
keyword
keyword
116456
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.